All In Biotech

Drug Trial Radar · NCT07185113

A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects

A Phase 1, Single Dose, Open-label Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Oct 29, 2025

Primary completion

Nov 4, 2025

Study completion Nov 4, 2025

Sponsor

Lead sponsor
GEn1E LifesciencesIndustry
Sponsor type
Industry
Collaborators
InClin, Inc.
First posted
Sep 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine the pharmacokinetics (how the body interacts with administered substances for the entire duration of exposure) of Gen-1124 in an oral formulation (taken by mouth) in healthy volunteers. It will also learn about the safety of Gen-1124. The main questions it aims to answer are: \- How does Gen-1124 interact with a human body? Researchers will look at how Gen-1124 interacts with the body and what side effects it may cause. Participants will: * Take Gen-1124 for a single dose * Remain in clinic for 2 days for checkups and tests * Recieve a phone call for a checkup 3 and 7 days after the single dose

Conditions

  • Healthy Adult Male

Interventions

  • GEn-1124Drug

    GEn-1124 will be administered to one single dose group of subjects dosed under fed (standardized meal) conditions. GEn-1124 will be administered as an oral capsule formulation containing GEn-1124.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK Endpoints - Plasma levelsTime frame: From enrollment to Day 2 discharge
  2. PK Endpoints - Plasma levelsTime frame: From enrollment to Day 2 discharge
  3. PK Endpoints - Plasma levelsTime frame: From enrollment to Day 2 discharge
  4. PK Endpoints - Plasma levelsTime frame: From enrollment to Day 2 discharge
  5. PK Endpoints - Plasma levelsTime frame: From enrollment to Day 2 discharge
  6. Safety Endpoints - Clinically significant changes to physical examTime frame: From informed consent/screening visit to Day 2
  7. Safety Endpoints - Clinically significant changes to ECG resultsTime frame: From informed consent/screening visit to Day 2
  8. Safety Endpoints - Clinically significant changes to clinical lab resultsTime frame: From informed consent/screening visit to Day 2
  9. Safety Endpoints - Clinically significant changes to vital signsTime frame: From informed consent/screening visit to Day 2
  10. Safety Endpoints - Changes to concomitant medicationsTime frame: From 14 days (or 5 half-lives, whichever is longer) prior to Screening through completion of the study.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research (NZCR)

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.